2023年3月17日,

協同醫療贏得聲望的大獎賽GALIEN在比利時的光電inc .提供的新聞分享本文協同醫療贏得比利時大獎賽GALIEN 2023年承諾設備獎協同醫療高興地宣布,他們已經獲得了大獎賽GALIEN 2023年在比利時有前途的醫療設備。陪審團的認可,我們的設備有可能帶來突破治療許多癲癇患者生活在恐懼的癲癇發作是極其令人鼓舞”,阿提拉Borbath增效的CEO和創始人醫療比利時,3月17日2023 / EINPresswire.com——協同醫療發達NAO臨床醫療設備公司。迷走神經刺激法,第一光電設備日前通過迷走神經刺激治療癲癇耐藥,高興地宣布,他們已經獲得了大獎賽Galien 2023年在比利時有前途的醫療設備。“我很高興所有的團隊協作醫療贏得了這個著名的和世界知名的獎項。陪審團的認可,我們的設備有可能帶來突破治療許多癲癇患者癲癇發作的生活在持續的恐懼是非常令人鼓舞的。很榮幸獲得這個獎項後不久被歐盟共同選定加速器項目。”阿提拉Borbath,協同醫療的CEO和創始人。“在操作方麵,我們最近完成了臨床前安全性研究成功非常有前途的結果。我們現在專注於準備First-In-Human研究中,預定明年,我們在美國食品藥品管理局申請。”他補充道。關於大獎賽Galien米娜Galien成立於1970年由羅蘭為了紀念Galien梅爾,醫學和現代藥理學的父親。全世界大獎賽Galien被認為是諾貝爾獎的生物製藥的研究。在比利時大獎賽的Galien由“《醫生。” About Epilepsy and Drug-Resistant Epilepsy Epilepsy is the 4th most common neurological disorder after migraine, stroke, and Alzheimer’s disease affecting 65 million people worldwide. The conventional medical treatment is with anti-epileptic drugs (AEDs) but 30% of the epileptic population see their symptoms poorly controlled with drugs and continue to have seizures that impair their health and daily life despite medication intake. They are consequently diagnosed with DRE (drug-resistant epilepsy). More than 1.15 million patients are currently waiting for an effective treatment, representing an estimated obtainable market of c.€20 billion. Development update of NAO.VNS – Optoelectonics for Vagus Nerve Stimulation NAO.VNS is a new generation neurostimulator that can reduce drug-resistant epileptic seizures by stimulation of the vagus nerve (VNS), using a new technology of materials to improve patients’ life. Neural stimulation is a clinically proven solution and the last resort for these patients. It involves the implantation of a small pacemaker connected to leads that deliver mild electric signals to the targeted nerve. NAO.VNS uses optical fibers and quartz, instead of metal wires and casing. Optoelectronics enables safe, personalized neural stimulation pulses in a magnetic field and renders NAO.VNS fully compatible with MRI or brain scans. The first in-vivo health and environmental safety study was successfully completed at the end of 2022. About Synergia Medical – www.synergia-medical.com Synergia Medical is an ISO 13485 certified medical device company that has developed NAO.VNS (Vagus Nerve Stimulation), the first optoelectronic neurostimulator for the treatment of drug-resistant epilepsy. Operational since 2016, Synergia Medical is based in Belgium and employs 30 employees. It was co-founded by Attila Borbath, CEO and Pascal Doguet, inventor of NAO.VNS. The company holds a portfolio of 9 patents in 15 families. James Palmer